Canine parvovirus (CPV) is the causative agent of canine parvovirus disease, a highly contagious viral disease that primarily affects young dogs, although unvaccinated adult dogs can also be affected. The virus belongs to the Parvoviridae family, genus Protoparvovirus, and is considered one of the most significant pathogens in small animal veterinary medicine due to its high morbidity and mortality rates.
CPV infection is characterized by predominantly gastrointestinal clinical signs, including severe vomiting, bloody diarrhea, anorexia, lethargy, and severe dehydration. The virus has a tropism for rapidly dividing cells, particularly intestinal crypts and bone marrow, resulting in severe enteritis and immunosuppression.
In very young puppies, the infection can also lead to viral myocarditis, a condition that is less common today but is associated with a high mortality rate. The destruction of intestinal cells promotes bacterial translocation, which can progress to septicemia and shock, worsening the clinical condition.
Canine parvovirus is transmitted primarily via the fecal-oral route, through direct contact with the feces of infected animals or indirect contact with contaminated environments, objects, utensils, and clothing. CPV is highly resistant in the environment and can remain viable for long periods, which makes it difficult to control the disease.
The impacts of canine parvovirus include high mortality rates in puppies, high costs associated with intensive care and hospitalization, as well as significant animal suffering. The disease poses a public health challenge, particularly in kennels, shelters, and areas with high dog populations.
Prevention of CPV infection relies primarily on proper vaccination, which is considered the most effective measure for controlling the disease. Proper vaccination protocols, combined with strict hygiene practices and the isolation of sick animals, are essential for reducing viral circulation.
Laboratory diagnosis of canine parvovirus can be performed using rapid antigen detection tests, serological assays, and molecular methods such as PCR, which allow for confirmation of infection with high sensitivity and specificity. Early diagnosis is essential for appropriate clinical management and for implementing containment measures.
Epidemiological surveillance, combined with health education for pet owners and adherence to vaccination protocols, is essential for controlling canine parvovirus. These measures help reduce the incidence of the disease, improve animal welfare, and strengthen veterinary public health practices.
*]:pointer-events-auto scroll-mt-[calc(var(–header-height)+min(200px,max(70px,20svh)))]” dir=”auto” tabindex=”-1″ data-turn-id=”request-WEB:fe9b6517-792e-400f-9654-1c43d01eef55-37″ data-testid=”conversation-turn-76″ data-scroll-anchor=”true” data-turn=”assistant”>
In this context, Bioperfectus’ rapid test for canine parvovirus (CPV) stands out as a practical screening tool to support clinical diagnosis and public health surveillance. The use of the rapid test enables the prompt identification of suspected cases directly at the veterinary clinic, allowing for the immediate implementation of measures such as isolation, rapid initiation of supportive care, and intensified environmental disinfection. Thus, the rapid test complements confirmatory laboratory methods, contributing to the early detection of CPV, the reduction of virus spread, and the strengthening of canine parvovirus control strategies, especially in kennels, shelters, and veterinary clinics.
